Shilpa Medicare shares hit a record high of Rs 753.85 on the NSE after the company posted record Q1 revenue and profit.

The company reported a consolidated net profit of Rs 101 crore for the first quarter of FY27, compared with Rs 47 crore in the same period last year. Revenue from operations rose 45% year-on-year to Rs 466 crore.

Operating performance also improved. EBITDA increased 48.6% to Rs 136.2 crore, while the EBITDA margin expanded to 29.25% from 28.52% a year earlier.

Growth came from several businesses. Revenue from the API division increased by nearly 15%, supported by both internal demand and higher external sales.

The company’s novel products business also delivered strong growth, with revenue more than doubling after excluding licensing income.

Its formulations business recorded healthy momentum as well. European formulations revenue rose 84% year-on-year to Rs 57 crore, helped by portfolio expansion and stronger market reach.

Domestic formulations revenue jumped 179%, reflecting solid demand in India. The quarterly performance follows a series of recent developments.

In June, Shilpa Biologicals, the company’s wholly owned arm, signed a co-development and supply agreement with Finland-based Orion Corporation for a Nivolumab biosimilar.

During July, India Ratings upgraded the credit ratings of Shilpa Medicare and Shilpa Pharma Lifesciences to IND AA-/Stable.

The company also said it remains on track to file the Semaglutide Drug Master File during the first half of FY27 and expects commercial supplies in Europe to begin in the second half of the financial year.

Shilpa Medicare shares closed at Rs 721.75, up 11.96% on the NSE after touching a record intraday high of Rs 753.85.

Discover the next big investment! Tradz by EquityPandits’ IPO screener helps you identify promising initial public offerings. Download Tradz by EquityPandit and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!